Home Drug IndexClinical Monograph

Ramipril Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antihypertensive

Subclass

Angiotensin-Converting Enzyme (ACE) Inhibitor

Speciality

Cardiology

Schedule (India)

Schedule H

Routes

Oral

Formulations

Tablets: 1.25 mg, 2.5 mg, 5 mg, 10 mg
Capsules (soft gelatin): 1.25 mg, 2.5 mg, 5 mg, 10 mg

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Hypertension

Parameter	Recommendation
Starting dose	2.5 mg once daily
Titration	Increase every 2–4 weeks based on blood pressure response
Usual maintenance dose	2.5–10 mg once daily (may be given in divided doses)
Maximum dose	10 mg/day

Clinical Notes:

In volume-depleted or diuretic-treated patients, initiate at 1.25 mg to minimise first-dose hypotension risk
Evening dosing may be preferred for non-dippers

2. Heart Failure (NYHA Class II–IV)

Parameter	Recommendation
Starting dose	1.25 mg once or twice daily
Titration	Double dose at 1–2 week intervals as tolerated
Usual maintenance dose	5 mg/day in 1–2 divided doses
Maximum dose	10 mg/day

Clinical Notes:

Initiate only after haemodynamic stabilisation with diuretics
Hold or reduce dose if symptomatic hypotension or rising creatinine (>30% from baseline)
Aim for target dose where tolerated; partial dosing still beneficial

3. Post-Myocardial Infarction with Left Ventricular Dysfunction

Parameter	Recommendation
Starting dose	2.5 mg twice daily (starting 3–10 days post-MI)
Titration	Increase over subsequent days toward target
Usual maintenance dose	5 mg twice daily
Maximum dose	10 mg/day

Clinical Notes:

Start only when patient is haemodynamically stable
Proven mortality benefit in post-MI LV systolic dysfunction (EF ≤40%)

4. Diabetic Nephropathy and Proteinuric Chronic Kidney Disease

Parameter	Recommendation
Starting dose	1.25–2.5 mg once daily
Titration	Adjust every 2–4 weeks based on BP, proteinuria, and renal function
Usual maintenance dose	2.5–10 mg once daily
Maximum dose	10 mg/day

Clinical Notes:

Provides renoprotection independent of blood pressure lowering
Acceptable to continue if creatinine rises <30% from baseline and potassium remains <5.5 mEq/L
Also beneficial in non-diabetic proteinuric CKD

Secondary Indications — Adults (Off-label)

Indication	Dose	Duration	Notes
Secondary stroke prevention (in hypertensive patients)	5–10 mg once daily	Long-term	OFF-LABEL — Evidence from HOPE trial; used in Indian practice for high-risk cardiovascular patients with hypertension
Atrial fibrillation with LVH (stroke risk reduction adjunct)	2.5–10 mg/day	Long-term	OFF-LABEL — Benefit from BP lowering and LVH regression; does NOT replace anticoagulation

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Indication: Hypertension in children ≥1 year (specialist-supervised use only)

Weight/Age Category	Starting Dose	Titration	Usual Maintenance	Maximum Dose
Children ≥1 year, <10 kg	0.05 mg/kg once daily	Increase at intervals ≥1 week	0.05–0.2 mg/kg/day	0.625 mg/day
Children ≥1 year, ≥10 kg	0.05 mg/kg once daily	Increase at intervals ≥1 week	0.05–0.2 mg/kg/day	2.5–5 mg/day

Safety and Monitoring:

Monitor blood pressure, serum creatinine, and potassium at baseline, 1 week after initiation, and regularly thereafter
Crushed tablets may be mixed with water for administration if needed

Secondary Indications — Paediatrics (Off-label)

Indication	Dose	Duration	Notes
Heart failure secondary to congenital heart disease	0.05–0.1 mg/kg/day in 1–2 doses	Long-term	OFF-LABEL — Specialist only — Used in paediatric cardiology units; requires preserved baseline renal function

Age Restriction Statement:

NOT RECOMMENDED in infants <1 year except under paediatric nephrology or cardiology specialist supervision due to immature renal physiology and limited safety data

Renal Adjustments

eGFR (mL/min/1.73m²)	Recommendation
30–60	Starting dose: 1.25–2.5 mg/day; titrate slowly with renal and potassium monitoring
<30	Maximum dose: 5 mg/day; initiate cautiously with frequent monitoring
Haemodialysis	Administer post-dialysis; drug is not significantly dialyzable; individualise dosing under specialist guidance
Peritoneal dialysis	Limited data; use with caution under specialist supervision

Hepatic adjustment

Contraindications

History of angioedema (idiopathic or associated with prior ACE inhibitor/ARB use)
Bilateral renal artery stenosis or stenosis of artery to solitary kidney
Pregnancy (2nd and 3rd trimester — absolute)
Hypersensitivity to ramipril or any ACE inhibitor
Concomitant use with aliskiren in patients with diabetes mellitus or eGFR <60 mL/min/1.73m²
Concomitant use with sacubitril/valsartan within 36 hours
Severe hypotension or cardiogenic shock

Cautions

Volume depletion or concurrent diuretic therapy — increased risk of first-dose hypotension
Hyperkalaemia risk — particularly in CKD, diabetes, elderly, or those on potassium-sparing agents
Aortic or mitral stenosis — risk of reduced coronary perfusion with hypotension
Hypertrophic cardiomyopathy with outflow obstruction
Pre-existing renal impairment — monitor closely for deterioration
Dual RAS blockade with ARBs — avoid unless under specialist supervision
Collagen vascular diseases (e.g., SLE, scleroderma) — increased risk of neutropenia
Black African patients — may have reduced efficacy and higher angioedema risk

Pregnancy

Aspect	Recommendation
Overall safety	Contraindicated in 2nd and 3rd trimesters — teratogenic effects include renal agenesis, skull hypoplasia, oligohydramnios, limb contractures
First trimester	Avoid unless no alternative exists; discontinue immediately upon confirmation of pregnancy
Preferred alternatives	Labetalol, methyldopa, nifedipine (as per Indian obstetric practice)
If inadvertently exposed	Serial ultrasound for fetal growth, renal function, amniotic fluid volume; neonatal monitoring post-delivery

Lactation

Aspect	Recommendation
Compatibility	Not recommended — limited human data; low-level excretion in breast milk expected
Preferred alternatives	Enalapril (if ACE inhibitor needed), labetalol, nifedipine
Drug levels in milk	Low (based on limited studies)
Infant monitoring	If exposure occurs: monitor for poor feeding, inadequate weight gain, hypotension, lethargy

Elderly

Aspect	Recommendation
Starting dose	1.25 mg once daily
Titration	Slower than standard; increase at 2–4 week intervals
Special risks	Orthostatic hypotension, falls, pre-existing renal impairment, hyperkalaemia
Monitoring	Renal function and serum potassium within 1 week of initiation and after each dose change

Major drug interactions

Drug/Class	Interaction	Management
Potassium-sparing diuretics (spironolactone, eplerenone, amiloride)	Significantly increased hyperkalaemia risk	Monitor potassium closely; avoid combination in renal impairment
Aliskiren	Dual RAS blockade increases hypotension, hyperkalaemia, AKI	Contraindicated in diabetes or eGFR <60
Sacubitril/valsartan	Markedly increased angioedema risk	Do not initiate ramipril within 36 hours of sacubitril/valsartan; washout required
Lithium	Increased lithium levels leading to toxicity	Avoid combination; if essential, monitor lithium levels frequently
ARBs (dual RAS blockade)	Hypotension, renal impairment, hyperkalaemia	Avoid unless specialist-directed in specific heart failure scenarios

Moderate drug interactions

Drug/Class	Interaction	Management
NSAIDs (including COX-2 inhibitors)	Reduced antihypertensive effect; increased renal impairment risk	Use lowest NSAID dose for shortest duration; monitor BP and renal function
Thiazide/loop diuretics	Enhanced hypotensive effect, especially initially	Consider temporary diuretic dose reduction before starting ramipril
Antidiabetic agents (insulin, sulfonylureas)	Enhanced hypoglycaemic effect	Monitor blood glucose, especially early in therapy
Allopurinol, immunosuppressants	Increased risk of leucopenia	Monitor complete blood count periodically
Potassium supplements	Additive hyperkalaemia risk	Avoid routine supplementation; monitor potassium
Antacids	Minor reduction in ramipril absorption	Separate administration by 2 hours if clinically significant

Common Adverse effects

Dry persistent cough (5–10%; class effect)
Dizziness and lightheadedness
Postural hypotension
Headache
Fatigue and asthenia
Hyperkalaemia
Transient rise in serum creatinine (initial)
Nausea, diarrhoea

Serious Adverse effects

Adverse Effect	Clinical Action
Angioedema (face, lips, tongue, larynx)	Immediate discontinuation; emergency airway management; do not rechallenge with any ACE inhibitor
Severe hypotension (especially first-dose)	Supine positioning, IV fluids, dose reduction or discontinuation
Acute kidney injury	Hold therapy; investigate reversible causes; may need specialist referral
Neutropenia/agranulocytosis	Monitor CBC in collagen vascular disease patients; discontinue if confirmed
Cholestatic jaundice/hepatitis	Rare; discontinue if liver enzymes significantly elevated
Anaphylactoid reactions	Reported during haemodialysis with high-flux membranes or LDL apheresis; avoid concomitant use

Monitoring requirements

Timing	Parameters
Baseline	Serum creatinine, eGFR, serum potassium, blood pressure; CBC in patients with collagen vascular disease
1–2 weeks post-initiation or dose change	Repeat creatinine, potassium, blood pressure
Long-term (every 3–6 months)	Renal function, potassium, blood pressure; assess for cough, symptoms of angioedema
Special populations	More frequent monitoring in elderly, CKD, heart failure, diabetes

Brands in India

Cardace (Sanofi)
Ramcor (Cipla)
Ramistar (Lupin)
Hopace (Emcure)
Aceten (Zydus Cadila)
Odipril (Sun Pharma)
Ramace (Glenmark)

Fixed-Dose Combinations (FDCs):

Ramipril + Hydrochlorothiazide
Ramipril + Amlodipine

Price range (INR)

Formulation	Approximate Price
Ramipril 2.5 mg tablet	₹1.50–3.00 per tablet
Ramipril 5 mg tablet	₹2.00–5.00 per tablet
Ramipril 10 mg tablet	₹3.00–7.00 per tablet

Notes:

Included in NLEM 2022; select brands under NPPA price control
Generic formulations widely available at lower cost
Government supply available through public health facilities

Clinical pearls

First-dose precaution: Always initiate at 1.25–2.5 mg in elderly, diuretic-treated, or volume-depleted patients to avoid significant first-dose hypotension.
Cough management: Dry cough occurs in 5–10% of patients; if persistent and distressing, switching to an ARB is appropriate rather than reducing dose.
Renal function changes: A rise in creatinine up to 30% from baseline is acceptable and does not mandate discontinuation, particularly in heart failure and CKD with proteinuria.
Target dosing in heart failure: Aim for evidence-based target doses (5 mg BD) where tolerated; undertreating reduces mortality benefit.
Avoid abrupt discontinuation: In stable heart failure or post-MI patients, abrupt cessation may precipitate clinical deterioration.
Potassium vigilance: Always check potassium within 1–2 weeks of starting therapy, especially in diabetics, CKD patients, and those on concomitant potassium-sparing agents.

Version

RxIndia v1.1 — 13 Jun 2025

Reference

CDSCO-approved product information
Indian Pharmacopoeia 2022
National List of Essential Medicines (NLEM) 2022
API Textbook of Medicine (11th Edition)
ICMR Guidelines on Hypertension Management
AIIMS Cardiology and Nephrology protocols
HOPE Trial (N Engl J Med 2000) — for off-label cardiovascular usage
IAP Drug Formulary — for paediatric dosing reference

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...